BC Extra | May 23, 2019
Financial News

How Bicycle, Ideaya fared in debuts as they join 2019’s growing IPO class

A pair of newly listed biotechs trended in opposite directions during first-day trading Thursday. Bicycle slipped 14% after pricing its IPO at the bottom end of its proposed range, while Ideaya was up 12% after...
BC Innovations | Apr 5, 2019
Targets & Mechanisms

Breaking up Hippo to tame proliferation

Drug developers are creating a new class of compounds that disrupt a protein-protein interaction in the Hippo pathway that goes awry in cancers and fibrotic diseases. At least two programs are poised to enter the...
BC Innovations | Sep 20, 2018
Distillery Therapeutics

Cancer

INDICATION: Melanoma Cell culture studies identified an inhibitor of Q209L-mutant Gα-q that could help treat uveal melanoma harboring the mutation. In HEK cell-based signaling and activity assays, a previously reported cyclic depsipeptide-based inhibitor of Gα-q...
BC Innovations | Nov 16, 2017
Emerging Company Profile

YAP off, YAP on

Vivace Therapeutics Inc. exploits opposite angles of the Hippo-YAP pathway, with first-in-class inhibitors that turn it off in cancers with activating mutations and activators that turn it on to enhance tumor immunogenicity in other cancers....
BC Innovations | Oct 24, 2017
Distillery Therapeutics

Inflammation

INDICATION: Asthma Patient sample and mouse studies suggest inhibiting Gα-q could help treat asthma. In ex vivo human bronchiole tissue, a Gα-q inhibitor decreased histamine-induced bronchoconstriction compared with vehicle. In two mouse models of allergic...
BC Innovations | May 23, 2017
Distillery Therapeutics

Cancer

INDICATION: Melanoma Cell culture studies suggest inhibiting PRKCD , PKCE or RASGRP3 could help treat GNAQ -mutant uveal melanoma. Levels of RASGRP3 were higher in five human GNAQ-mutant uveal melanoma cell lines than in four human...
BC Innovations | Jun 9, 2016
Distillery Therapeutics

Therapeutics: ADP-ribosylation factor 6 (ARF6); G protein q polypeptide (GNAQ; G-ALPHA-q)

Cancer INDICATION: Melanoma Cell culture and mouse studies suggest inhibiting ARF6 could help treat GNAQ-mutant uveal melanoma. In two human GNAQ-mutant uveal melanoma cell lines, siRNA targeting ARF6 decreased colony-forming units and proliferation compared with...
BC Innovations | Jun 4, 2015
Distillery Therapeutics

Therapeutics: Metabotropic glutamate receptor subtype 5 (mGluR5; GRM5);

Neurology INDICATION: Schizophrenia In vitro and rat studies identified a positive allosteric modulator (PAM) of mGluR5 that could help treat schizophrenia. Optimization of a previously identified mGluR5 PAM and testing in rat astrocytes and hippocampal...
BC Innovations | May 21, 2015
Distillery Therapeutics

Therapeutics: Guanine nucleotide binding protein (G protein) q polypeptide (GNAQ; G-ALPHA-q); calcineurin; transient receptor potential cation channel subfamily

Renal disease INDICATION: Nephropathy; renal failure Mouse studies suggest inhibiting GNAQ , calcineurin or TRPC6 could help treat focal segmental glomerulosclerosis (FSGS). In kidney podocytes, signaling between GNAQ and calcineurin activates TRPC6. In a mouse model...
BC Innovations | Aug 21, 2014
Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Cancer G protein q polypeptide (GNAQ) (G-ALPHA-q); MAS-related GPR member X1 (MRGPRX1; GPCR; SNSR4) In vitro and cell culture studies suggest the small molecule compound...
Items per page:
1 - 10 of 16